Brigit Biofarmaka Teknologi Tbk. vs Trimegah Karya Pratama Tbk. — how do they compare? Brigit Biofarmaka Teknologi Tbk. trades at Rp252 (market cap 172.82B, 218.7K 24h volume), while Trimegah Karya Pratama Tbk. trades at Rp150 (market cap 312.02B, 65.66M 24h volume). The key difference: Trimegah Karya Pratama Tbk. is the larger of the two by market cap, and Trimegah Karya Pratama Tbk. is more actively traded (65.66M versus 218.7K). Which is the better fit depends on your goals.
| OBAT | UVCR | |
|---|---|---|
Market Cap | 172.82B | 312.02B |
Volume | 218.7K | 65.66M |
Lot | 2.19K | 656.62K |
Turnover | 53.51M | 9.71B |
Average Price | 244.66 | 147.94 |
Value | 53.51M | 9.71B |
Indicative Equilibrium Price | 252 | 150 |
Indicative Equilibrium Volume | 48 | 8.52K |
Trailing returns across standard periods
Latest headlines on both assets
PT. Brigit Biofarmaka Teknologi Tbk. (the Company) was established based on Notarial Deed No. 103 dated December 14, 2015 of Yoerista Arya Megasari, S.H., M.Kn., Notary in Sukoharjo. The company starts production commercially in 2018.
Read more on OBAT →PT Trimegah Karya Pratama Tbk (the Company) was established based on Notarial Deed No. 21 dated July 7, 2017 of Netty Maria Machdar, S.H. The Company started its commercial operations in 2018. The Company’s immediate parent company is PT Trimegah Sumber Mas, which was established and domiciled in Indonesia, while its ultimate Parent Company is PT Hutama Mulia Rajawali, which was established and domiciled in Indonesia.
Read more on UVCR →